MorphoSys, immatics enter immuno-oncology deal

MorphoSys AG (Xetra:MOR; Pink:MPSYF) partnered with immatics biotechnologies GmbH (Tuebingen, Germany) to develop antibodies against undisclosed cancer targets recognized by T cells.

MorphoSys will gain access to an undisclosed number of immatics' tumor-associated peptides (TUMAPs), which MorphoSys will use to develop antibodies to treat solid and hematological cancers. immatics discovers TUMAPs with its XPRESIDENT antigen discovery platform, which uses mass spectrometry, genomics, biochemistry and immunology to identify the conformation of the antigen that most closely resembles how it appears on cancer cells. ...